Published in TB and Outbreaks Week, August 24th, 1998
"(Our) results provided additional proof of the association of specific rpoB mutations with the development of rifamycin resistance and corroborate previous reports of the usefulness of rpoB genotyping for predicting rifamycin-resistant phenotypes," D.L. Williams and colleagues wrote ("Contribution of rpoB Mutations to Development of Rifamycin Cross-Resistance in Mycobacterium tuberculosis," Antimicrobial Agents and Chemotherapy, July 1998;42(7):1853-1857).
The rifamycins include rifampin,...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of TB and Outbreaks Week